Recent Updates
Recently added Catalysts

OKI-179

Phase 1

Advanced Solid Tumors | Small molecule | Oncology |OnKure Therapeutics, Inc.|Last Updated: Dec 5, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment34
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03931681A Study of OKI-179 in Patients With Solid TumorsPHASE1 COMPLETED 34 — — May 1, 2019Nov 1, 2021Dec 5, 2021 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
OKI-179DRUGOKI-179 single agent
Unlock Study Design Details
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence